Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Successful Scale-Up in the Production of CodeXol® Detergent Alcohols

Published: Tuesday, June 18, 2013
Last Updated: Tuesday, June 18, 2013
Bookmark and Share
Codexis and Chemtex achieve key milestone in commercial development of bio-based chemicals from non-food cellulosic biomass.

Codexis and Chemtex have announced the successful scale-up in the production of CodeXol® detergent alcohols using cellulosic sugars.

The scale-up was achieved at a 1,500 liter demonstration facility at Chemtex’s R&D complex in Tortona, Italy and is a key milestone in the ongoing effort initiated by the two companies to develop a fully integrated biomass to detergent alcohols technology.

A combination of Chemtex’s commercially proven PROESA®cellulosic sugar technology and Codexis’ CodeXyme® 4X cellulase enzymes was used to produce cellulosic sugars from non-food biomass, while the CodeXol® detergent alcohol fermentation process technology - which includes Codexis’ proprietary microorganism strain - converted these cellulosic sugars to detergent alcohols.

Guido Ghisolfi, President of Chemtex, said, “While the PROESA® technology is proven at commercial scale for the production of cellulosic ethanol - as evidenced by the successful start-up of our commercial facility in Crescentino, Italy - this achievement is further proof that our platform cellulosic sugar technology is best-in-class for producing a broad range of bio-based chemicals using sustainable, non-food sources of biomass. It also validates our conviction that scaling up these technologies beyond the lab is key to enabling the learning curve towards commercial viability.”

John Nicols, President and CEO of Codexis, said, “This scale-up of CodeXol® detergent alcohols represents what we believe is the world’s first successful large scale effort to produce commercially relevant detergent alcohols from a cellulosic biomass feedstock. We believe this scale-up demonstrates the robustness and efficacy of our CodeXyme®cellulase enzymes and the ability of our CodeXol® detergent alcohol technology to produce detergent alcohols at commercial specification with the potential to decrease manufacturing costs below incumbent production costs.”

Detergent alcohols are used to manufacture surfactants, which are key, active cleaning ingredients in consumer products such as shampoos, liquid soaps and laundry detergents.

The annual global market for detergent alcohols, which are currently manufactured from natural oils and fats and petrochemicals, is approximately $4 billion and is expected to reach $5.5 billion by 2020.

Codexis and Chemtex initiated an effort in 2011 to produce these high-value chemicals from sustainable, low-cost and non-food sources of biomass, which has the potential to offer attractive production economics compared to incumbent production routes.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Codexis Signs Multi-year Extension of Contract with Merck
Agreement extension to supply enzyme used in manufacture of sitagliptin.
Tuesday, December 29, 2015
Codexis Announces CodeEvolver Technology License Agreement with Merck
Codexis to receive $5 million in upfront payment.
Friday, August 07, 2015
Codexis Sign Technology License Agreement with GSK
Codexis to receive up to $25M of initial payments, plus additional milestone and royalty opportunities.
Wednesday, July 16, 2014
Codexis Sells its Hungarian Operations
The Hungarian subsidiary is sold for $1.5 million to Intrexon Corporation.
Friday, March 14, 2014
Codexis Appoints Patrick Yang to Board of Directors
Dr. Yang brings significant experience in pharmaceutical manufacturing and process development.
Friday, February 28, 2014
Purolite and Codexis Announce Collaboration
Purolite Corporation and Codexis, Inc. announced a joint collaboration to develop and market immobilized enzymes for the pharmaceutical industry.
Thursday, July 18, 2013
Codexis Appoints Vice President of Sales and Marketing
Appointment of Scott Watson as Vice President.
Thursday, June 06, 2013
Codexis Selected for Third Presidential Green Chemistry Award in Seven Years
The award, from the U.S. Environmental Protection Agency, is for the development of an efficient biocatalytic process to manufacture simvastatin, a leading drug for treating high cholesterol.
Tuesday, June 19, 2012
USPTO Grants Codexis Patent for Enzymes Used in Hep-C Therapeutics
Highlights how Codexis platform enables breakthrough biocatalytic processes.
Friday, May 18, 2012
Nature Highlights Advancements in Biocatalysis
Highlights potential impact on the production of biofuels, renewable chemicals, and pharmaceuticals.
Friday, May 11, 2012
Codexis Awarded Biofuels Enzyme Patent
Patent is cornerstone for company’s cellulosic biofuels program.
Wednesday, March 28, 2012
Codexis Names Wes Bolsen VP and Chief Marketing Officer
Mr Bolsen will have responsibility for the company's corporate marketing and communications.
Tuesday, December 06, 2011
Veteran Chemical Executive to Lead Codexis do Brasil
Achilles Antonio Clement has been named Director, Latin America with responsibility for managing Codexis' expanding role in Latin America.
Thursday, October 13, 2011
Codexis Licenses new Drug Metabolite Profiling and Lead Diversification Technology from Caltech
Codexis will incorporate the licensed technology in development of new R&D productivity tools for use by the pharmaceutical industry.
Thursday, August 30, 2007
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Gene That Lowers Heart Attack Risk Identified
Individuals with a rare twelve-letter deletion from a gene on chromosome 17 have significantly reduced non-HDL cholesterol levels and a 35% lower than average risk of heart disease.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
"Sunscreen" Gene May Guard Against Melanoma
USC-led study reveals that melanoma patients with deficient or mutant copies of the gene are less protected from harmful ultraviolet rays.
Real-Time Imaging of Embryo Development Could Pave the Way
Researchers at IMCB have developed advanced microscopy technologies to monitor embryo development for more effective human reproduction therapies.
Testing Non-Breast/Ovarian Cancer Genes
Researchers have found that expanding gene panel beyond breast/ovarian cancer genes in these patients does not add any clinical benefit. Instead, testing has produced more questions than answers.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!